Picower Institute for Learning and Memory

CaringKind to Host the 27th Annual Forget-Me-Not Gala, on June 12th at The Pierre, with a Star-Studded Lineup Including David Hyde Pierce, Peter Gabriel, Q-Tip, and more

Retrieved on: 
Monday, June 5, 2023
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Cotton swab, Music, Education, Master of Ceremonies (Sweden), Schneps Media, Dementia, Picower Institute for Learning and Memory, Tony, Public policy, Research, MIT, Ceremony, Spectrum disorder, Lenox Hill Hospital, MD, Patient, Isabel, Memory, National Bioscience Award for Career Development, Learning, Psychiatry, Master, Grammy Awards, Neurology, The Pierre, Caregiver, Gala, Northwell Health, Rock and Roll Hall of Fame, Nursing, Residential care, Alzheimer's disease, Reverberation

The Forget-Me-Not Gala is a way for CaringKind to continue to raise essential funds to support the myriad of programs they offer.

Key Points: 
  • The Forget-Me-Not Gala is a way for CaringKind to continue to raise essential funds to support the myriad of programs they offer.
  • David Hyde Pierce, who received the Tony's Isabelle Stevenson Award for his longtime advocacy and support for Alzheimer's care and research, will serve as the Master of Ceremonies for the evening.
  • At the Gala, CaringKind will honor three outstanding individuals and groups for their significant contributions to the Alzheimer's community.
  • For further information about the Forget-Me-Not Gala, including donations, please visit www.caringkindnyc.org/gala or contact Courtney Dawson at 646-744-2932 or [email protected] .

Axial Therapeutics Announces Key Research and Development Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics

Retrieved on: 
Wednesday, March 29, 2023
Picower Institute for Learning and Memory, Bachelor of Science in Human Biology, Operation, Therapy, Senior, Doctor of Philosophy, Pharmacokinetics, Research, MIT, DSM-IV codes, Science, Development, St. Lawrence University, Vanderbilt, MD, Translational research, Patient, Memory, Spectrum, Drug discovery, Toxicology, Growth, Bacteria, IND, Flexion Therapeutics, Massachusetts Institute of Technology, Disease, Pharmaceutical industry, Chemistry, Axial, Pharmacology

WOBURN, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced key promotions in its research and development organization. These promotions recognize the Axial team’s scientific and clinical expertise and support its continued growth to advance the company’s pipeline, including the ongoing Phase 2b clinical trial in autism and preclinical evaluation of a development candidate for Parkinson’s Disease. Preclinical R&D promotions include: Rebecca Senter, PhD, to Vice President, Head of Preclinical Research and Development, Radka Graf, to Director, Preclinical Development and Operations and Chris Oalmann, PhD, to Senior Director, Chemistry. In addition to these promotions, Gabriel Belfort, MD, PhD, who was appointed Vice President, Clinical Development Science and Operations in 2022, also was promoted to Senior Vice President, Clinical Development Science and Operations.

Key Points: 
  • WOBURN, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced key promotions in its research and development organization.
  • These promotions recognize the Axial team’s scientific and clinical expertise and support its continued growth to advance the company’s pipeline, including the ongoing Phase 2b clinical trial in autism and preclinical evaluation of a development candidate for Parkinson’s Disease.
  • Preclinical R&D promotions include: Rebecca Senter, PhD, to Vice President, Head of Preclinical Research and Development, Radka Graf, to Director, Preclinical Development and Operations and Chris Oalmann, PhD, to Senior Director, Chemistry.
  • “The significant advancement of our pipeline of novel microbiome therapeutics has only been possible because of our dedicated and talented team.

Luminopia Announces FDA Approval of Digital Therapeutic that Uses TV Shows to Improve Vision in Children with Lazy Eye

Retrieved on: 
Wednesday, October 20, 2021
Software, Research, Pharmaceutical, Optical, Consumer, Technology, Clinical Trials, Science, Children, Audio, Video, FDA, Other Technology, Health, Safety, Virtual reality, MD, Compliance, HMD, Technology, Amblyopia, Strabismus, Myopia, American Academy, Ageing, Anisometropia, Patient, FDA, Astigmatism, Atropine, Food, Cleveland, VR, Cataract, Picower Institute for Learning and Memory, Eye, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Visual acuity, Brain, Hospital, Randomized controlled trial, Cleveland Clinic, HMDS, Learning, Sesame Workshop, Severe cognitive impairment, MIT, LogMAR chart, Therapy, Doctor of Philosophy, Parent, De novo, Pharmacy, Far-sightedness, Memory, Physician, Pharmaceutical industry, Telescopic sight, Luminopia One, Amblyopia4, Luminopia, LUMINOPIA ONE, AMBLYOPIA4, LUMINOPIA

Luminopia One allows patients to watch therapeutically modified TV shows and movies to improve their vision within a virtual reality (VR) headset.

Key Points: 
  • Luminopia One allows patients to watch therapeutically modified TV shows and movies to improve their vision within a virtual reality (VR) headset.
  • The FDA approval of a new digital therapy with robust clinical evidence for children affected by amblyopia is a major development.
  • The idea of prescribing TV shows and movies to treat amblyopia in children instead of eye patches or eye drops is an exciting prospect.
  • Luminopia One is the first FDA-approved digital therapeutic for a neuro-visual disorder in children, indicated to improve vision in children with amblyopia.

Luminopia One, a Digital Therapeutic for Amblyopia, Demonstrates Safety and Efficacy in Phase 3 Pivotal Trial

Retrieved on: 
Tuesday, September 14, 2021
Children, Technology, Health, General Health, Optical, Research, Software, Consumer, Science, Clinical Trials, Parenting, LogMAR chart, Patient satisfaction, Amblyopia, Food, American Academy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neuro, FDA, Sesame Workshop, Learning, Massachusetts Institute of Technology, Clinical study design, Memory, De novo, Patient, Picower Institute for Learning and Memory, Software, Net, Algorithm, Far-sightedness, VR, MIT, Severe cognitive impairment, Safety, Cleveland, Strabismus, Therapy, NPS, Ageing, Myopia, Hospital, MSCE, Cleveland Clinic, Cataract, Review, Brain, Astigmatism, Randomized controlled trial, American Academy of Ophthalmology, Eye, Parent, Virtual reality, Atropine, Visual cortex, Pharmaceutical industry, Telescopic sight, Medical device, Luminopia One, Amblyopia5, Luminopia, LUMINOPIA ONE, AMBLYOPIA5, LUMINOPIA

The published study was a Phase 3 multicenter, randomized controlled clinical trial designed to evaluate the safety and efficacy of Luminopia One to treat amblyopia in children aged 4-7.

Key Points: 
  • The published study was a Phase 3 multicenter, randomized controlled clinical trial designed to evaluate the safety and efficacy of Luminopia One to treat amblyopia in children aged 4-7.
  • A link to the publication, Randomized Controlled Trial of a Dichoptic Digital Therapeutic for Amblyopia, can be found here: https://www.aaojournal.org/article/S0161-6420(21)00682-5/fulltext .
  • Luminopia One has been validated in multiple clinical trials, including a Phase 3 pivotal trial that demonstrated its safety and efficacy in children aged 4-7 for the treatment of amblyopia.
  • Luminopia is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients.

IFF Elects Dr. Li-Huei Tsai to Board of Directors

Retrieved on: 
Wednesday, October 30, 2019
Food, Beverage, Home Goods, Cosmetics, Retail, Specialty, Massachusetts Institute of Technology, Picower Institute for Learning and Memory, Li-Huei Tsai, Euronext, IFF, Tel Aviv Stock Exchange, Science and technology in the United States, Middle East, Medical research

IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, nutrition, announced that Dr. Li-Huei Tsai, Picower Professor and Director of the Picower Institute for Learning and Memory at the Massachusetts Institute of Technology, was elected to the Company's Board of Directors, effective immediately.

Key Points: 
  • IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, nutrition, announced that Dr. Li-Huei Tsai, Picower Professor and Director of the Picower Institute for Learning and Memory at the Massachusetts Institute of Technology, was elected to the Company's Board of Directors, effective immediately.
  • Dr. Tsai is an exceptionally talented individual and were pleased she is joining IFFs Board, said IFF Chairman and CEO Andreas Fibig.
  • Dr. Tsai is co-founder of Cognito Therapeutics, a company focused on developing a device-based approach to treating Alzheimers.
  • At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), were using Uncommon Sense to create what the world needs.